Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating invasive pneumococcal disease (“IPD”) in pediatric and adult patient populations. The latest deal builds on the existing collaboration between SNY and SK bioscience to develop and commercialize a 21-valent PCV (PCV21) for the pediatric patient population. Sanofi also said that the companies commenced a phase III program for the PCV21 pediatric vaccine last week. Per management, this is the first-ever PCV containing more than 20 serotypes to enter a phase III study targeting infants and toddlers. Year to date, shares of Sanofi have lost 4% against the industry's growth of 1.4%. Zacks Investment Research Image Source: Zacks Investment Research SNY's Expanded Deal for Developing PCV21 Per the expanded collaboration agreement, Sanofi and SK bioscience will jointly fund all researc
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- 1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street [Yahoo! Finance]Yahoo! Finance
- These CEO's reveal their top festive reads for the year [Fortune]Fortune
- Olympian Jordan Chiles is setting her sights on a new goal: raising awareness of type 1 diabetes [Fortune]Fortune
- SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccinesGlobeNewswire
SNY
Sec Filings
- 12/23/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/13/24 - Form 6-K
- SNY's page on the SEC website